back arrow Back

Admissibility of medicine for claim

reply Share
02 Apr, 2022 by  R Lalittha

Ujvira (T-DM1) or trastusumab-emtansine to treat Her2 + CA Breast in adjuvant treatment is prescribed as protocol by treating doctor. Insurer rejects claim on grounds that it is "mono clonal antibody" and hence exceeded sublimits. whereas , its a conjugate biosimilar of the two medicines mentioned above. Can you please clarify?


like like
Health Insurance

2 Answer

08 Apr, 2022
connect with advisor

Dear Lalittha,

Monoconol Anitibody is classified under Modern Treatment. Many plans have a limit defined for such treatments. Kindly cross check your plan for sub limits towards modern treatment. Currently it seems the limit has been reached and hence the claim is not paid.


Rohit Dhingra

like like
icon-comment 0 Comments
icon-reply Reply
09 Apr, 2022
R Lalittha

Sir it's very kind of you to reply to the query. Not sure whether this medicine is to be treated as monoclonal antibody are a chemo drug.

Thanks for your valuable time


like like
icon-comment 0 Comments
icon-reply Reply

Tired of dealing with call centers!

Get a professional advisor for life!

Rs. 1799


Limited Period Offer


Discover the best tips for insurance every week!

Beshak is not regulated by the Insurance Regulatory and Development Authority of India (IRDAI) and does not have any alliance or association with any Insurance business.
© Copyright 2022 Beshak Solutions Pvt. Ltd. All Rights Reserved.

Disclaimer: The content on the website is purely for information purposes for the public at large, and does not constitute personal financial advice for a specific individual reader.
If you are reading this, it means you love reading the fine print. Why not get paid for what you love doing - Join us by writing to now 🙂